Physician profile
Austen Knapp
NPI 1871098111
$16,056.62
in general payments reported to CMS, 2019-2025
17 companies · $12K in 2025
The $12K reported for 2025 was more than what 96% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.99 · 2020: $17.97 · 2021: $1,452 · 2022: $674 · 2023: $1,171 · 2024: $557 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,800 · Food and Beverage: $2,322 · Travel and Lodging: $1,091 · Grant: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,800.00 |
| Food and Beverage | $2,322.04 |
| Travel and Lodging | $1,090.60 |
| Grant | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $8,579.87 | 2022-2025 | Stellaris Elite, Stellaris, Stellaris |
| Harrow Eye, LLC | $2,931.08 | 2025 | Triesence |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,200.47 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $636.04 | 2023-2025 | Eylea Hd, Eylea |
| Regeneron Pharmaceuticals, INC. | $600.00 | 2023 | |
| Apellis Pharmaceuticals, INC. | $447.84 | 2022-2025 | Syfovre |
| Astellas Pharma US INC | $361.58 | 2024-2025 | Izervay |
| Alcon Vision LLC | $268.93 | 2021-2023 | Ngenuity |
| Alimera Sciences, INC. | $134.96 | 2022-2024 | Yutiq, Iluvien |
| Ani Pharmaceuticals, INC. | $129.39 | 2025 | Purified Cortrophin Gel, Yutiq, Iluvien |
| Biogen, INC. | $128.04 | 2023 | |
| Glaukos Corporation | $121.41 | 2022-2023 | Istent Inject Trabecular Micro-Bypass System Model G2-M-Is |
| Allergan, INC. | $119.66 | 2019-2021 | |
| Ocular Therapeutix, INC. | $104.25 | 2021 | |
| Genentech USA, INC. | $103.53 | 2024-2025 | Vabysmo, Susvimo |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $95.49 | 2022 | |
| Genentech, INC. | $94.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austen Knapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.